Short Interest in Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY) Decreases By 86.7%

Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY) was the recipient of a significant decrease in short interest in October. As of October 31st, there was short interest totalling 200 shares, a decrease of 86.7% from the October 15th total of 1,500 shares. Based on an average daily volume of 2,300 shares, the days-to-cover ratio is currently 0.1 days.

Clinuvel Pharmaceuticals Price Performance

Shares of OTCMKTS:CLVLY traded up $0.09 during trading on Thursday, hitting $9.04. The company’s stock had a trading volume of 285 shares, compared to its average volume of 2,702. The company has a 50-day moving average of $9.55 and a 200-day moving average of $9.76. Clinuvel Pharmaceuticals has a 12 month low of $8.42 and a 12 month high of $12.06.

Clinuvel Pharmaceuticals Increases Dividend

The business also recently declared a dividend, which was paid on Monday, September 30th. Shareholders of record on Monday, September 9th were issued a dividend of $0.0299 per share. The ex-dividend date was Monday, September 9th. This is a positive change from Clinuvel Pharmaceuticals’s previous dividend of $0.03.

Clinuvel Pharmaceuticals Company Profile

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).